E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Subjects presenting moderate allergic conjunctivitis to birch pollen |
|
E.1.1.1 | Medical condition in easily understood language |
Subjects presenting moderate allergic conjunctivitis |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Eye Diseases [C11] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10010741 |
E.1.2 | Term | Conjunctivitis |
E.1.2 | System Organ Class | 10021881 - Infections and infestations |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the efficacy of NAABAK® compared to FLUCON®, assessed by the measure of the amount of major birch pollen allergen required to trigger a conjunctival response in subjects presenting moderate symptoms of allergic conjunctivitis caused by birch pollen. |
|
E.2.2 | Secondary objectives of the trial |
1. To evaluate the time required to obtain a positive Abelson score in both subjects groups during an allergen exposure in ALYATEC environmental chamber. 2. To evaluate the onset of conjunctival symptoms during an allergen exposure in ALYATEC environmental chamber. 3. To appreciate the correlation between the dose of allergen required to induce a positive conjunctival provocation unitary test and the dose required to induce a conjunctival response, during an exposure to birch pollen allergen in ALYATEC environmental chamber.
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Adults aged 18-65 years, with moderate manifestations of allergic conjunctivitis with or without allergic rhinitis. • The history of moderate conjunctivitis in the last 2 years according to EAACI recommendations. • Positive Prick tests (papule diameter greater than 6 mm compared to the negative control), • IgE specific to Bet v1 greater than 0.70 kUI / l • Individual conjunctival challenge test positive for birch pollen (Abelson score ≥ 5).
|
|
E.4 | Principal exclusion criteria |
• Personal or family history of glaucoma • Eye Hypertension • Eye surgery within 6 months of inclusion in the study • Other forms of allergic conjunctivitis: Vernal and atopic keratoconjunctivitis, giant papillary conjunctivitis, perannual allergic conjunctivitis • Non-specific conjunctival hyperreactivity • Herpetic keratitis • Viral diseases of the cornea and conjunctiva • Tuberculous lesions and untreated bacterial infections of the eye; • Fungal diseases of ocular structures • Affection of the sclera or cornea • Dry eye syndrome • dysimmune diseases that may interfere with the study (dry syndrome in the context of inflammatory rheumatism) • Allergic pathology (rhinitis, conjunctivitis) not controlled • Uncontrolled asthma requiring a short-acting B2 mimetic more than twice a week or requiring that taken within the last 15 days.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
• Allergen quantity needed to induce a positive conjunctival response (Abelson score ≥ 5).
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
At Expo 1 (D1 + D2) and at Expo 2 (D1 + D2) |
|
E.5.2 | Secondary end point(s) |
1. Time to reach a positive conjunctival response (Abelson score ≥ 5) in both treatments groups 2. Evaluation of the onset of conjunctival symptoms during birch allergens exposures (Abelson score by physician, TOSS and conjunctivitis VAS) 3. Correlation between the the dose of allergen required to induce a positive conjunctival provocation unitary test and the dose required to induce a conjunctival response in the EEC 4. Safety : VEMS measurements |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
- Abelson score, TOSS and conjunctivitis VAS : every 10 minutes during the first hour, then every 20 minutes for the next 3 hours - VEMS measurements : every 30 minutes during exposures |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | No |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
Investigator mask / blind |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Last visit of the last subject undergoing the trial |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | |